Two corporate investors have joined Hookipa Biotech of Austria's €20 million ($27.5 million) series B financing. Existing investors Sofinnova Partners and Forbion Capital Partners led the financing, with three new investors, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners joining the round.
Hookipa has developed a replication-defective viral vector platform called Vaxwave, which can stimulate antibody and CD8+ T cell immunity. The...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
